Making use of the Internet to increase, as much as possible, the number of people who can live longer and healthier lives, and to reduce, as much as possible, the amount of unnecessary medical costs.

Paradigm Shifts for Healthcare

One in three people are over the age of 65 in Japan, with medical costs continuing to balloon to over 40 trillion yen.

Over the years, M3 has invested in roughly 30 healthcare related venture companies tackling this social problem, in line with its corporate mission of “making use of the Internet to increase, as much as possible, the number of people who can live longer and healthier lives, and to reduce, as much as possible, the amount of unnecessary medical costs,” of which 9 have IPOed so far.

At this juncture, we have established the “1P1Y Fund” corporate venture fund in order to accelerate progress in 7P projects*1 in actualizing the M3 mission.

Investments through this fund and utilization of resources across M3’s ecosystem will boost the development and new business creation across the ventures in the fund, ultimately to bring paradigm shifts within the medical community.

*1 7P projects: New service expansion (AI based diagnostics, genetic testing, consolidation of stroke rehabilitation centers, etc.) that extend beyond pharmaceutical marketing, and their integration into comprehensive solutions for issues across the healthcare industry.

Past Investments

M3’s History of
Added Value Provision

The 1P1Y Fund provides extensive additional value and collaboration with the M3 group in addition to funding, in order to support the strong growth of the invested companies.

Endorsement backed by M3's extensive expertise within the healthcare industry

#1 in market capital growth rate amongst the top 100 companies in Japan.

Became the first company to be included across all companies established since the year 2000, to be included in the Nikkei 225 Index, in October 2019.

A globally recognized company

#1 ranking Japanese company (#5 globally) in the 2017 Forbes Most Innovative Growth Companies

True experience-based management advice

Management Strategy

  • Business recommendations based on expertise across areas such as internet businesses (including platform business) and healthcare businesses (including AI)
  • IPO and post-IPO growth management guidance based on M3's experience of its own establishment in 2000, IPO in 2004, and TSE1 listing in 2007

Equity Story and IR

  • Advice for compelling equity stories to maximize corporate value ahead of IPO
  • Domestic and overseas investor introductions, IR advice, IR material creation support, etc.

Strategic Alliances

  • Proficiency in strategic alliances with large corporates.
  • M&A advice based on M3’s extensive track record of corporate acquisitions (as both buyer and seller).

Business Value Creation

Concrete business value creation support using M3’s platform of over 6 million global physician members

Sales and Marketing

  • Market research (including idea and seeds feasibility and marketability assessment) and promotional activity utilizing tools such as
  • Sales support employing M3 group resources

Pharmaceuticals and Product Development

  • Regulatory counsel and support for rapid, low cost market launch of product
  • PMDA negotiation support
  • Clinical study and trial execution support

Overseas Expansion

  • Advice regarding overseas development (US, EU, China, India, etc.)
  • Collaboration with M3 group overseas entities

Human Resources

  • Support for recruitment of healthcare field professionals
  • Staff sourcing and exchanges across the M3 group

Engineering Aptitude Including AI Development


  • CTO/VPoE and top engineering talent recruitment advice
  • Management support for engineer organizations
  • Suggestions and joint organization of engineers’ study group and networking activities

All of the above, in addition to traditional venture capital functionalities

No conflict of interest with M3

Autonomy of the invested company will be well-respected. The invested companies are free to exit with partners besides M3. M3 is in principle unlikely to purchase the invested company, unless requested by the invested company for such consideration.

No conflict of interest with M3

Compatibility with M3

Compatibility with M3 Compatibility with M3

1P1Y Fund Overview

Total Investment Line
10 billion yen (average of several hundred million yen per company to a maximum of approximately 2 billion yen)
Investment Region
Domestic and Global
Investment Target
Startups, Listed Companies, Pharmaceutical/Medical Device Pipelines, etc.
Investment Themes
Themes in which collaboration with M3 or M3 Group can be expected (AI, Medical Devices (including software), Advanced Medicine, Rare Diseases, Health Management, etc.)
Investment Target Stage
All Stages from Seed/Early to Late

Current Portfolio

Striving to assist growth and new business creation through utilization of resources across the M3 group ecosystem

[Name] EVERING Co.
[Established] February 2020
[Address] Nihonbashi Front 1F, 3-6-2 Nihonbashi, Chuo-ku, Tokyo, Japan
[President & CEO] Takeshi Kawada
[Business activities] Manufacture and sale of smart ring devices
[Name] aptpod, Inc.
[Established] December 2006
[Address] Yotsuya Tosei Building 3F 4-3 Yotsuya Shinjuku-ku Tokyo , JAPAN
[President & CEO] Junichi Sakamoto
[Business activities] Provide a comprehensive framework for high-speed and large-volume data collection, transmission in the industrial scene
[Name] Cardio Intelligence Inc.
[Established] 2019
[Address] 1-29-5, Higashiazabu Minato-ku, Tokyo , JAPAN
[President & CEO] Yuichi Tamura
[Business activities] Development of Arrhythmia Diagnosis System Using Artificial Intelligence
[Name]Africa Health Holdings Limited
[Address]Cayman Islands
[President & CEO]Sangu Delle
[Business activities]Management and operation of hospitals, clinics, pharmacies and laboratories in Africa
[Name] Perseus Proteomics Inc.
[Established] February 2001
[Address] 4-7-6, Komaba Meguro-ku, Tokyo , JAPAN
[President & CEO] Takuya Yokokawa
[Business activities] Development of antibody drugs
[Name] Connect Inc.
[Established] May 2018
[Address] 2-15-5 Minamiaoyama, Minato-ku, Tokyo, Japan
[President & CEO] Junichi Ushiba
[Business activities] Development, manufacturing, and sales of brain-machine interface devices applied for neurorehabilitation
[Name] CellAxia Inc.
[Established] January 2017
[Address] 1-10-9 Nihonbashi, Horidome-cho, Chuo-ku, Tokyo, Japan
[President & CEO] Makoto Seki
[Business activities] Research and development of regenerative medicine
[Name] PECO Inc.
[Established] December 2014
[Address] 3-5-1 Sendagaya, Shibuya-ku, Tokyo, Japan
[President & CEO] Jun Okazaki
[Business activities] Management of one of the largest media specializing in pets in Japan, etc.
[Name] Shape Memory Medical Inc.
[Established] 2009
[Address] 807 Aldo Avenue, Suite 109 Santa Clara, CA 95054 USA
[President & CEO] Edward Ruppel
[Business activities] Development of medical devices in the cardiovascular field
[Name] Kringle Pharma, Inc.
[Established] December 2001
[Address] 207 Saito Bio Incubator 7-7-15 Saitoasagi, Ibaraki, OSAKA 567-0085, JAPAN
[President & CEO] Kiichi Adachi
[Business activities] Research and development of HGF protein medicines

Company Overview

M3, Inc.
Akasaka Intercity 10th floor 1-11-44 Akasaka Minato-ku, Tokyo 107-0052 JAPAN
September 2000
Representative Director
Itaru Tanimura
28,810 million yen
Listed Exchange
Tokyo Stock Exchange First Section (Securities code 2413)
7,127(group total as of March 2020)


April 09, 2021
Investment in EVERING Co.
March 15, 2021
Investment in aptpod, Inc.
March 02, 2021
Investment in Cardio Intelligence Inc.
March 01, 2021
Capital Alliance with Africa Health Holdings Limited ~ Solution for Medical Facilities, Pharmacies and Laboratories in Africa ~
December 28, 2020
Kringle Pharma, Inc. lists on the TSE Mothers. (Ticker: 4884)
November 12, 2020
Joint Development and Distribution Agreement with Fuji Pharma
November 10, 2020
Investment in Perseus Proteomics Inc.
October 30, 2020
Investment in Connect Inc.
September 10, 2020
Investment in CellAxia Inc.
August 14, 2020
Investment in PECO Inc.
May 14, 2020
Investment in Shape Memory Medical, Inc.
April 22, 2020
Full Scale Roll Out of CVC “1Y1P Fund” ~ Dedicated Website Launched to Fortify Investment Activity ~
March 2, 2020
Capital alliance with Kringle Pharma, Inc. ~ 7P Initiative: Development of Therapeutic Drugs for Spinal Cord Injury ~
October 25, 2019
Launch of Internal Corporate Venture Capital Fund “1P1Y (1 Person 1 Yen) Fund”


For any related inquiries, please email us, and our administrative office will revert.

Email address:

© 1P1Y. All Rights Reserved.